Squarepoint
PALI icon

Squarepoint’s Palisade Bio PALI Stock Holding History

Squarepoint’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$19.8K Sell
14,636
-71,342
-83% -$139K ﹤0.01% 4333
2026
Q2 		$180K Sell
85,978
-110,961
-56% -$218K ﹤0.01% 4090
2026
Q1 		$345K Sell
196,939
-125,151
-39% -$228K ﹤0.01% 3603
2025
Q4 		$757K Buy
+322,090
New +$619K ﹤0.01% 2851

Other funds holding PALI

Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Creek Drive Management Group
Creek Drive Management Group San Francisco, California $368M AUM 23.05% 1-Year Est. Return

Squarepoint's PALI Position: Q3 2026 in Review

Squarepoint reduced its Palisade Bio (PALI) stake by 83% in Q3 2026, selling an estimated $139K and leaving 14,636 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4333.

Squarepoint first reported a position in PALI in Q4 2025 and has held it in 4 quarters since. The position peaked at $757K in Q4 2025. 54 funds tracked by Wall St. Rank hold PALI as of Q3 2026.

  • Squarepoint held 14,636 shares of Palisade Bio worth $19.8K as of Q3 2026.
  • Squarepoint sold 71,342 Palisade Bio shares in Q3 2026, an estimated $139K.
  • Palisade Bio made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4333 holding.
  • Squarepoint first reported a position in Palisade Bio in Q4 2025 and has held it in 4 quarters since.
  • Squarepoint's Palisade Bio position peaked at $757K in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Palisade Bio as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.